Scientific quality: The manuscript describes a case report of recurrent undifferentiated embryonal sarcoma of the liver in adult patient treated by Perbrolizumab. The topic is within the scope of the WJG.

(1) Classification: Grade B;
(2) Summary of the Peer-Review Report: Reviewer think this manuscript is a very interesting and significant case report. However, readers would like to see more data.For example, the state of macrophage and T cell distribution in the tumor, macro photography, MRI, ultrasound images, the expression of B7-H3 in the tumor, Granzyme, etc;

Response:

Based on the reviewer's comments, further immunohistological staining of CD68, CD8 and CD4 were used to detect macrophage and T cell distribution in the tumor, and the results were showed in revised figure 5 and Page 4 line 26 to 28.

In this case, we applied CT or PETCT to evaluate the tumor status of patient, so we can not provided MRI or ultrasound images.

The immune checkpoint PD-1 and its receptor B7-H1 (PD-L1) are successful therapeutic targets in cancer but less is known about other B7 family members. B7-H3 is an immune checkpoint from the B7 family. B7-H3 was found to inhibit T-cell proliferation [1-3]. The molecule has also been linked to the decrease in secretion of IFN-γ, TNF-α, and other cytokines, which allows for immune escape [4]. The similarities between B7-H3 and PD-L1 have given researchers reason to target B7-H3 in novel immunotherapeutic treatments. While recent studies showed that coexpression of B7-H3 with PD-L1 and B7-H4 was relatively low, suggesting a nonredundant biological role of these targets[5]. In this case, we intended to find biomarkers to predict the effect of PD-1 antibodies, B7-H3 as a B7 family member can not predict the effect of PD-1 antibodies. So we did not detect the expression of B7-H3. And due to the epidemic of COVID-19 and restricted international Air Transportation Services, we can not acquire the antibody of B7-H3 and granzyme. So, we can not provide the immunohistological staining of B7-H3 and granzyme.

References

1. Ling V, Wu PW, Spaulding V, Kieleczawa J, Luxenberg D, Carreno BM, Collins M. Duplication of primate and rodent B7-H3 immunoglobulin V- and C-like domains: divergent history of functional redundancy and exon loss. Genomics. 2003;82:365–377.

2. Prasad DV, Nguyen T, Li Z, Yang Y, Duong J, Wang Y, Dong C. Murine B7-H3 is a negative regulator of T cells. J Immunol. 2004;173:2500–2506.

3. Suh WK, Gajewska BU, Okada H, Gronski MA, Bertram EM, Dawicki W, Duncan GS, Bukczynski J, Plyte S, Elia A, Wakeham A, Itie A, Chung S, Da Costa J, Arya S, Horan T, Campbell P, Gaida K, Ohashi PS, Watts TH, Yoshinaga SK, Bray MR, Jordana M, Mak TW. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol. 2003;4:899–906.

4. Ma J, Ma P, Zhao C, Xue X, Han H, Liu C, Tao H, Xiu W, Cai J, Zhang M. B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy. Oncotarget. 2016;7:29480–29491.

5.Altan M , Pelekanou V , Schalper K A , et al. B7-H3 expression in NSCLC and its association with B7-H4, PD-L1 and Tumor Infiltrating Lymphocytes[J]. Clinical Cancer Research, 2017:5202.

(3) Format: There are 5 figures. A total of 16 references are cited, including 4 references published in the last 3 years. There are no self-citations. 2 Language evaluation: Classification: Grade B. A language editing certificate issued by AJE was provided.

3 Academic norms and rules: Please provided the signed Conflict-of-Interest Disclosure Form and Copyright License Agreement, no academic misconduct was found in the CrossCheck detection and Bing search.

4 Supplementary comments: This is an unsolicited manuscript. The study was supported by National Natural Science Foundation of China.The topic has not previously been published in the WJG. The corresponding author has not published articles in the BPG.

5 Issues raised: (1) I found the authors did not provide the approved grant application form(s). Please upload the approved grant application form(s) or funding agency copy of any approval document(s);

Response: we have provided the approved grant application form.

(2) I found the authors did not provide the original figures. Please provide the original figure documents. Please prepare and arrange the figures using PowerPoint to ensure that all graphs or arrows or text portions can be reprocessed by the editor;

Response: we have provided the original figure documents.

(3) I found the "Case Presentation" did not meet our requirements. Please re-write the "Case Presentation" section, and add "FINAL DIAGNOSIS", "TREATMENT", and "OUTCOME AND FOLLOW-UP" section to the main text, according to the Guidelines and Requirements for Manuscript Revision;

Response: We re-write this section according to the Guidelines and Requirements for Manuscript Revision.

(4) the author should number the references in Arabic numerals according to the citation order in the text. The reference numbers will be superscripted in square brackets at the end of the sentence with the citation content or after the cited author's name, with no spaces.

Response: We have corrected all these errors in the manuscript.